Literature DB >> 9456285

Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats.

L Brown1, J Miller, A Dagger, C Sernia.   

Abstract

In rats, monocrotaline causes pulmonary vascular damage leading to pulmonary hypertension, right ventricular hypertrophy, and eventually heart failure. This study determined the inotropic and chronotropic responses in isolated cardiac tissues from pulmonary hypertensive rats (single treatment with monocrotaline, 105 mg/kg) to noradrenaline, forskolin, EMD 57033 (calcium sensitizer), and calcium chloride. Further, vasoconstrictor responses to noradrenaline, 5-hydroxytryptamine (5-HT), and KCl were measured in isolated pulmonary artery and thoracic aortic rings. Marked right ventricular hypertrophy was evident 4 weeks after treatment; at 6 weeks, treated rats additionally showed symptoms of severe heart failure. Pulmonary hypertension led to marked increases in pulmonary artery responses to 5-HT and to decreases in positive inotropic responses in right ventricular papillary muscles to all compounds except calcium chloride. The development of heart failure maintained or increased these changes. Positive chronotropic responses were unchanged. In the right ventricle, beta1-adrenoceptor density decreased only in heart failure; beta2-adrenoceptor density was unchanged. The densities of both beta-adrenoceptor subtypes were decreased in the lungs but increased in the liver of pulmonary hypertensive rats. The functional changes in the failing human heart are similar to those in rats with monocrotaline-induced right ventricular hypertrophy. This may be a useful model to define adequate therapy in human right ventricular failure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9456285     DOI: 10.1097/00005344-199801000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Rhythmical contractions in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats.

Authors:  Akihiko Kiyoshi; Tomohisa Ishikawa; Ken-ichi Hayashi; Yoshiyuki Iwatsuki; Kunio Ishii; Koichi Nakayama
Journal:  Pflugers Arch       Date:  2003-09-27       Impact factor: 3.657

Review 2.  Right ventricular adaptation and failure in pulmonary arterial hypertension.

Authors:  John J Ryan; Jessica Huston; Shelby Kutty; Nathan D Hatton; Lindsay Bowman; Lian Tian; Julia E Herr; Amer M Johri; Stephen L Archer
Journal:  Can J Cardiol       Date:  2015-01-29       Impact factor: 5.223

Review 3.  The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.

Authors:  John J Ryan; Stephen L Archer
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  Acute effects of levosimendan in experimental models of right ventricular hypertrophy and failure.

Authors:  Mads D Vildbrad; Asger Andersen; Sarah Holmboe; Steffen Ringgaard; Jan M Nielsen; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

5.  Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence.

Authors:  Katarzyna Sztormowska-Achranowicz; Zbigniew Jankowski; Ivan Kocić
Journal:  Pharmacol Rep       Date:  2020-07-06       Impact factor: 3.024

6.  Supplementing exposure to hypoxia with a copper depleted diet does not exacerbate right ventricular remodeling in mice.

Authors:  Ella M Poels; Nicole Bitsch; Jos M Slenter; M Eline Kooi; Chiel C de Theije; Leon J de Windt; Vanessa P M van Empel; Paula A da Costa Martins
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

7.  Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series).

Authors:  Kewal Asosingh; Serpil Erzurum
Journal:  Pulm Circ       Date:  2017-12-21       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.